NEW YORK, NY / ACCESSWIRE / June 4, 2022 /
CatchMark Timber Trust, Inc. CTT
Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of CTT to PotlatchDeltic Corp. for 0.23 common shares of PotlatchDeltic stock for each common share of CTT.
If you are an investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
TherapeuticsMD, Inc. TXMD
Lifshitz Law PLLCannounces investigation into possible breach of fiduciary duties in connection with the sale of TXMD to EW Healthcare Partners in a deal valued at approximately $177 million. Pursuant to the merger agreement, TXMD stockholders will receive $10 in cash for each share of TXMD common stock owned.
If you are an investor, and would like information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Turning Point Therapeutics, Inc. TPTX
Lifshitz Law PLLCannounces investigation into possible breach of fiduciary duties in connection with the sale of TPTX to Bristol Myers Squibb for $76.00 per share is fair to Turning Point shareholders.
If you are an investor, and would like information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING.© 2022 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com
SOURCE: Lifshitz Law PLLC
https://www.accesswire.com/703877/Lifshitz-Law-PLLC-Announces-Investigation-of-CTT-TXMD-and-TPTX
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.